Veru adjourns 2024 annual meeting of shareholders to june 27, 2024

Miami, fl, june 18, 2024 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that its annual meeting of shareholders scheduled for today (annual meeting) was convened and adjourned without any business being conducted due to lack of a required quorum.
VERU Ratings Summary
VERU Quant Ranking